AstraZeneca launches new Zomig form in USA
AstraZeneca has introduced a new rapid-dissolving formulation of itsantimigraine drug Zomig (zolmitriptan) in the USA, based on CIMA Labs' DuraSolv drug delivery technology. Zomig-ZMT, marketed as Zomig Rapimelt in Europe - where it was launched in 1999 - can be taken without water and is indicated for the treatment of acute migraine attacks, with or without aura.
Sales of Zomig Rapimelt, which is available in 18 countries outside the USA, increased 33% in the first quarter of 2001 compared to the same period of 2000, while overall Zomig sales advanced 5% to L66 million ($95 million; Marketletter April 30).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze